5.05 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||5.02 x 4000|
|Ask||5.40 x 900|
|Day's Range||5.04 - 5.28|
|52 Week Range||3.75 - 19.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.83|
Stock Research Monitor: NLNK, OHRP, and ONCS LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want a free Stock Review on OMER sign up now at www.wallstequities.com/registration . On Monday, benchmark ...
NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Central ...
NewLink Genetics Corporation today announced that data from two Phase 2 studies of indoximod, used in combination with other agents, were presented at the 2018 American Society of Clinical Oncology Annual Meeting.
AMES, Iowa, May 30, 2018-- NewLink Genetics Corporation announced today that the company will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018, at 8:00AM ET.. A live ...
AMES, Iowa, May 16, 2018-- NewLink Genetics Corporation today announced that abstracts from two Phase 2 studies of indoximod, used in combination with other agents, are now available on the website of ...
The Ames, Iowa-based company said it had a loss of 49 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
AMES, Iowa, May 03, 2018-- NewLink Genetics Corporation today reported consolidated financial results for the first quarter 2018 and reviewed recent highlights and upcoming milestones.. “NewLink Genetics ...
AMES, Iowa, May 01, 2018-- NewLink Genetics Corporation today announced the appointment of Matthew L. Sherman, M.D. to the Company's Board of Directors. In connection with this appointment, the Company's ...
AMES, Iowa, April 30, 2018-- NewLink Genetics Corporation announced today that the company will participate in the following investor conferences:. Deutsche Bank 43 rd Annual Health Care Conference on ...
|Downgrade||Cantor Fitzgerald: Buy to Neutral||4/9/2018|
|Downgrade||SunTrust Robinson Humphrey: Buy to Hold||4/9/2018|
|Downgrade||Baird: Outperform to Neutral||4/9/2018|
|Initiated||Bank of America: to Buy||10/13/2017|
|Upgrade||Baird: Neutral to Outperform||9/8/2017|
|Upgrade||Jefferies: Hold to Buy||9/8/2017|
Full Time Employees: 76
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia. The company is also developing NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a clinical stage indoleamine-2, 3-dioxygenase pathway inhibitor. In addition, it is developing tergenpumatucel-L and dorgenmeltucel-L that are in Phase II clinical trials for treating patients with advanced lung cancer and melanoma; and CRLX101 and CRLX301, which are in early clinical development to treat patients with advanced solid malignancies. The company has strategic collaboration agreement with AstraZeneca to evaluate the combination of indoximod and durvalumab, an anti-PD-L1 monoclonal antibody for treating patients with metastatic pancreatic cancer; Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe and Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.